What do you think of Shanghai Free Trade Zone Fund’s investment in Bangyao Biotech’s more than 200 million yuan Series B financing?

Bangyao Biotech is an innovative pharmaceutical company focusing on the field of gene and cell therapy. It was established in 2013. On November 14, 2022, Bangyao Bio announced the completion of a Series B financing of more than 200 million yuan. This round of financing was led by Shanghai Free Trade Zone Fund, followed by Oriental Fuhai, Tasly Capital, Beida Fund, Gopher Asset, etc. cast.

The success of this financing first demonstrates the market’s recognition and support for Bangyao Biotech. With the mission of "leading innovation through gene editing, developing breakthrough therapies, and benefiting all mankind", Bangyao Biotech's business positioning and development direction have received positive response from the market. Secondly, this also reflects the investment boom in China’s biopharmaceutical industry. Driven by national policies, the biopharmaceutical industry has developed rapidly and attracted a large amount of investment. Finally, this financing will also provide more financial support for the future development of Bangyao Biotech, which will help it continue to promote the transformation and implementation of cell and gene drugs, increase its efforts to further accelerate its global R&D layout, and help global life sciences development, bringing hope to patients with genetic diseases, malignant tumors and autoimmune system diseases around the world.

In general, Bangyao Biotech’s receipt of 200 million yuan in Series B financing led by Shanghai Free Trade Zone Fund is an affirmation of its business development and market prospects, and also heralds the Chinese biopharmaceutical industry. The investment boom will continue to heat up.